On Jul. 28, 2023, the U.S. FDA approved RiVive, 3 milligram (mg) naloxone hydrochloride nasal spray for over-the-counter (OTC), nonprescription use for the emergency treatment of known or suspected opioid overdose.

This was the second nonprescription naloxone product the agency has approved, helping increase consumer access to naloxone without a prescription.